Non-mechanical Digoxin Micronization via Precipitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current micronization processes for digoxin are inadequate as they often result in non-homogeneous particle sizes, leading to variations in bioavailability and activity, and can cause partial degradation of the drug during mechanical treatment, which affects its stability and safety.
Innovation Solution
A non-mechanical process involving the concentration and purification of digoxin in an organic solvent, followed by precipitation and treatment with methanol to achieve a micronized form with a particle size of 20-30 micrometers, free from degradation products, ensuring high purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If mechanical micronization processes (milling, grinding) are used to reduce digoxin particle size, then the dissolution rate and bioavailability are improved, but the drug undergoes partial degradation and loses stability
Solution Approach 1:
The patent replaces mechanical micronization processes (milling, grinding) with a chemical precipitation process. Digoxin is precipitated from a concentrated solution in a non-aqueous solvent, forming fine particles without mechanical impact. This substitution eliminates mechanical degradation while achieving the desired particle size reduction and uniformity, resolving the contradiction between manufacturing precision and drug stability.
Solution Approach 2:
The patent utilizes phase transition by precipitating digoxin from a concentrated solution in a non-aqueous solvent. The transition from dissolved state to solid precipitate forms fine, uniform particles with controlled size distribution. This phase transition approach achieves particle size reduction without mechanical forces, maintaining drug stability while improving dissolution characteristics.
2Area of stationary object
If mechanical treatment is applied to reduce particle size, then the specific surface area increases and dissolution rate improves, but degradation products are formed reducing purity
Solution Approach 1:
The patent replaces mechanical size reduction methods with chemical precipitation in a non-aqueous solvent. This process generates fine particles with high specific surface area through controlled crystallization rather than mechanical breakdown, avoiding the formation of degradation products and preserving drug purity while achieving the desired surface area for improved dissolution.
3Productivity
If standard micronization processes are used, then particle size is reduced for better absorption, but homogeneity of particle size varies between drug lots
Solution Approach 1:
The patent employs controlled phase transition through precipitation from concentrated non-aqueous solutions. By optimizing solvent selection, concentration, and precipitation conditions, the process achieves consistent particle size distribution (predominantly 2-20 micrometers) across different production batches. This reproducible phase transition mechanism ensures homogeneous particle size and consistent absorption efficiency, resolving the variability issue between drug lots.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process produces a highly homogeneous and stable micronized digoxin powder that meets pharmaceutical release standards, maintaining the drug's activity and safety by avoiding mechanical degradation, thus ensuring consistent bioavailability and therapeutic efficacy.
Implementation Method 1
the solution is further concentrated, obtaining the precipitation of digoxin
Implementation Method 2
The recovered precipitate consists in a digoxin with particle size comprised between 20 and 30 micrometers for at least 90% by weight of the obtained particles
Data Source
AI summary
New non-mechanical process of micronization, capable to reduce the particle size of digoxin from ordinary level to a selected micrometer range. Micronization is obtained via a specific treatment, to be performed on a purified and concentrated digoxin solution in an organic solvent. The purified and concentrated digoxin solution is obtainable via a sequence of solvent treatments; then, after reaching the required concentration, the solution is further concentrated, obtaining the precipitation of digoxin; the reaction mixture is then added with methanol under stirring for a suitable time. The recovered precipitate consists in a digoxin with particle size comprised between 20 and 30 micrometers for at least 90 % by weight of the obtained particles, and is exempt from degradation products.